Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,069

Aaron Schacht — EVP, Innovation, Regulatory + BD, Elanco — Well-Being Of Animals, People And Planet

Advancing the well-being of animals, people and the planet — aaron schacht — executive vice president, innovation, regulatory & business development, elanco.

Aaron Schacht is Executive Vice President: Innovation, Regulatory + Business Development at Elanco (https://www.elanco.com/), an American pharmaceutical company which produces medicines and vaccinations for pets and livestock, and which until 2,019 was a subsidiary of Eli Lilly and Company.

Prior to this, Mr. Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache.

In 2,012 Mr. Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry.

In 2,002 during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up.

Continue reading “Aaron Schacht — EVP, Innovation, Regulatory + BD, Elanco — Well-Being Of Animals, People And Planet” | >

The U.S. could be on the verge of a productivity boom, a game-changer for the economy

Economists have learned that new technological breakthroughs usually don’t cause a jump in productivity right away. The technology needs time to marinate so companies can test how best to deploy it in their industry. Brynjolfsson argues artificial intelligence and machine learning have now simmered long enough to make a dramatic difference. Others are not as convinced.

Rapid adoption of robots and artificial intelligence during the pandemic combined with a rebound in government investment is making some economists optimistic about a return of a 1990s economy with widespread benefits.

Neural Network Models of the Future – The Key to Unlocking How Our Brain Works

Summary: Researchers discuss different current neural network models and consider the steps that need to be taken to make them more realistic, and thus more useful, as possible.

Source: University of Plymouth.

Neuroscience is a field most obviously associated with medicine and/or psychology. However, my background in physics and computer science enables me to explore, and further understand, how the brain computes and stores information, identifying the underlying physical mechanisms and the interplay between them.

These sniffer dogs are learning to smell the coronavirus

As the disease swept the globe and scientists deployed tools such as polymerase chain reaction tests to detect the novel coronavirus in people, a team of researchers at the University of Pennsylvania’s School of Veterinary Medicine worked to determine if dogs could also be trained to find infections.

The proof-of-concept study, published in April in the journal PLOS ONE, showed that the virus has an odor that trained dogs can identify in urine and saliva. Now, the researchers—with the help of Tuuka, Griz, Toby, Rico, and Roxie—are examining whether canines can sniff out coronavirus’ scent in sweaty T-shirts.

If the dogs can accurately detect it on clothing, they could patrol places such as airports and stadiums to sniff out the virus in public settings.

What Temperature Kills Coronavirus (COVID-19)?

SARS-CoV-2, the new coronavirus that causes COVID-19, is sensitive to high temperatures.

Research shows it can be quickly killed at 70°C (158°F). It’s possible that slightly lower temperatures may also be effective, but these require a longer exposure time.

Aside from laundry, there aren’t many temperature-related ways to safely and effectively kill the new coronavirus in your home. Additionally, some temperature-related methods can actually be harmful.

AI Networks Based on Human Brain Connectivity Can Perform Cognitive Tasks

Artificial neural networks modeled on real brains can perform cognitive tasks.

A new study shows that artificial intelligence networks based on human brain connectivity can perform cognitive tasks efficiently.

By examining MRI data from a large Open Science repository, researchers reconstructed a brain connectivity pattern, and applied it to an artificial neural network (ANN). An ANN is a computing system consisting of multiple input and output units, much like the biological brain. A team of researchers from The Neuro (Montreal Neurological Institute-Hospital) and the Quebec Artificial Intelligence Institute trained the ANN to perform a cognitive memory task and observed how it worked to complete the assignment.

/* */